Smoking Cessation Aids Market to Grow with a CAGR of 7.37% through 2031F

Increase in the awareness of health concern and Rise in Digital Smoking Cessation Solutions is expected to drive the Global Smoking Cessation Aids Market growth in the forecast period, 2027-2031F.

According to TechSci Research report, “Smoking Cessation Aids Market – Global Industry Size, Share, Trends, Competition Forecast & Opportunities, 2031F”, the Global Smoking Cessation Aids Market stood at USD 25.23 Billion in 2025 and is expected to reach USD 38.66 Billion by 2031 growing with a CAGR of 7.37% in the forecast period. 

Smoking cessation aids are gaining stronger traction as smoking becomes less socially accepted and more consumers align quitting with healthier, prevention focused lifestyles. Smoking related health risks and stronger tobacco control policies are also pushing cessation support into mainstream care, while digital tools and clinical guidance are making structured quit attempts more practical than before. This is increasing interest in nicotine replacement therapies, counseling, and app based programs, especially as healthcare systems recognize that quitting support works better when behavioral and pharmacological approaches are combined. The biggest challenge remains affordability and availability, particularly in lower income markets where cessation medicines can still be scarce or too expensive for sustained use, limiting uptake even when motivation to quit is high. For Instance, WHO says more than 750 million tobacco users want to quit but 70% still lack access to effective cessation services, while Kenvue’s nicotine gum and patch became the first WHO prequalified nicotine replacement therapies in 2024.

Browse over XX market data Figures spread through XX Pages and an in-depth TOC on "Global Smoking Cessation Aids Market”

The Global Smoking Cessation Aids Market is segmented into product, end-user, regional distribution, and company.

Electronic cigarettes are emerging as the fastest moving product segment in the global smoking cessation aids market because many smokers see them as a more flexible transition option than conventional combustible tobacco. They appeal to users who want nicotine delivery that feels familiar while still allowing gradual control over intake, which makes them especially relevant for smokers attempting stepwise reduction rather than abrupt cessation. Product innovation has also improved their appeal, with better device design, rechargeable formats, flavor variety, and adjustable nicotine strengths helping manufacturers reach both first time switchers and repeat users. Wider online availability and growing consumer awareness around harm reduction have further strengthened adoption in several markets, even as regulators continue to debate long term public health implications. For Instance, the World Health Organization reported that the number of countries regulating or banning electronic nicotine delivery systems rose from 122 in 2022 to 133 in 2024, showing how quickly this category has become central to global cessation and nicotine policy discussions.

The online channel is becoming the fastest growing end user route in the smoking cessation aids market as consumers increasingly prefer private, convenient, and always available access to quit support. Digital storefronts allow users to compare nicotine replacement products, vaping alternatives, and behavioral support tools in one place, which reduces friction in the purchase journey and makes repeat buying easier. This channel is also benefiting from wider smartphone use, telehealth familiarity, subscription models, and home delivery, all of which fit well with the recurring nature of quit attempts and refill needs. Online ecosystems are especially attractive for smokers who may feel uncomfortable seeking help face to face, since they offer discretion alongside personalized content, reminders, and follow up support. For Instance, a randomized controlled trial involving 530 adult smokers found that 44.5 percent of Quit Genius users were abstinent at four weeks versus 28.7 percent in the control group, and 74 percent were still actively engaging with the app at the primary outcome.

Asia Pacific is positioned as the fastest growing regional market for smoking cessation aids because it combines a large tobacco using population with rising health awareness and stronger government intervention across major countries. Demand is being lifted by a broader shift toward preventive health, especially in urban populations where consumers are becoming more willing to spend on nicotine replacement products, counseling, and digital quit tools. The region is also benefiting from tighter tobacco control measures, public education campaigns, quitline expansion, and greater visibility of smoking related disease, which together are pushing more smokers toward structured cessation pathways. Growth is further supported by better retail and online access, making cessation products more reachable for a wider group of users. For Instance, India’s National Tobacco Control Programme now covers all 36 states and union territories and around 612 districts, and the government says the number of tobacco users declined by 8.1 million in the second round of the Global Adult Tobacco Survey. 

Major companies operating in Global Smoking Cessation Aids Market are:

• Pfizer Inc.
• GlaxoSmithKline PLC
• Hoffmann-La Roche AG
• Novartis AG
• Johnson and Johnson
• Bayer AG
• Cipla Ltd
• Takeda Pharmaceuticals Co. Ltd
• British American Tobacco PLC
• Kimree Technology Inc
• Imperial Tobacco Ltd

Download Free Sample Report

Customers can also request for 10% free customization on this report.

“Technological Advancements in Smoking Cessation Aids and changing lifestyle stigma are key drivers of the Smoking Cessation Aids and supplement market. In recent years, The global trend towards health-conscious living is driving individuals to make healthier choices. Quitting smoking aligns with this lifestyle shift, and cessation aids support this transition, making it more likely for people to quit successfully. The growing consumer emphasis on preventative healthcare products has enhanced production and marketing efforts. To meet the demands of the market, manufacturers are increasingly incorporating cutting-edge technologies with high production efficiency. Rising consumer acceptance and continuous product innovation will further ensure the growth of the Smoking Cessation Aids market in the coming years”, said Mr. Karan Chechi, Research Director of TechSci Research, a research-based management consulting firm.

“Smoking Cessation Aids Market- Global Industry Size, Share, Trends, Opportunity, and Forecast, Segmented By Product (Nicotine Replacement Therapy, Drugs, electronic Cigarettes, Others), By End-User (Hospital Pharmacies, Online Channels, Retail Pharmacies, Other), By Region & Competition, 2021-2031F”, has evaluated the future growth potential of Global Smoking Cessation Aids Market and provides statistics & information on market size, structure and future market growth. The report intends to provide cutting-edge market intelligence and help decision makers take sound investment decisions. Besides, the report also identifies and analyzes the emerging trends along with essential drivers, challenges, and opportunities in Global Smoking Cessation Aids Market.

Contact

TechSci Research LLC

420 Lexington Avenue, Suite 300,

New York, United States- 10170

Tel: +1-332-258-6602

Email: [email protected]

Website: www.techsciresearch.com